Hao Shuai, Liu Jialing, Tuo Jingjing, Wang Li, Li Wei, Liu Ming, Shuang Pengzhan, Li Nan
Center of Oncology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
Department of Oncology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Transl Cancer Res. 2025 May 30;14(5):2661-2676. doi: 10.21037/tcr-24-2058. Epub 2025 May 9.
Glioblastoma has high malignancy, treatment challenge, poor prognosis and survival. It takes place mostly in the frontal lobe, and it significantly impacts late-life activities. Therefore, the establishment of a survival model for frontal glioblastoma patients is of great significance for optimizing the treatment for patients. The aim of this study is to identify risk factors for frontal glioblastoma, to construct survival models, and to provide strong evidence for patients and doctors to apply radiotherapy to frontal glioblastoma.
Independent risk factors for frontal glioblastoma patients were identified and survival models were constructed based on information obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Clinical data on patients pathologically diagnosed with frontal glioblastoma were screened. A nomogram was constructed based on the training group to verify the clinical validity of the model.
A total of 2,063 patients were included. There were 1,444 patients assigned to the training group, according to a random number method, and the remaining 619 patients were included in the validation group. Cox multivariate analysis based on 1,444 data from the training group showed that age, tumor hemiorism, metastasis, surgery, chemotherapy and radiotherapy were significantly correlated with the prognosis, with P values less than 0.05. In the training group, the concordance index (C-index) for overall survival (OS) and cancer-specific survival (CSS) of the cohort was 0.712 and 0.710, respectively. Calibration, receiver operating characteristic curve and decision curve analysis for OS showed a good agreement between the actual and predicted probability of survival. A total of 225 cases were screened out for analysis after 1:1 matching with a caliper value of 0.02. The median survival time of patients receiving radiotherapy was 7 months and that of those without radiotherapy was 5 months, hazard ratio =1.067, P values less than 0.05.
Age over 60 years old, space-occupying lesions across the midline, surgery not performed, radiotherapy not performed, and without chemotherapy are poor prognostic factors for frontal glioblastoma patients. Radiation therapy can significantly improve OS and CSS in frontal glioblastoma patients. The nomogram developed in this study has the potential for clinical application.
胶质母细胞瘤恶性程度高,治疗具有挑战性,预后和生存率差。它多发生于额叶,对患者的晚年活动有显著影响。因此,建立额叶胶质母细胞瘤患者的生存模型对于优化患者治疗具有重要意义。本研究旨在确定额叶胶质母细胞瘤的危险因素,构建生存模型,并为患者和医生对额叶胶质母细胞瘤应用放射治疗提供有力依据。
基于从监测、流行病学和最终结果(SEER)数据库获得的信息,确定额叶胶质母细胞瘤患者的独立危险因素并构建生存模型。筛选经病理诊断为额叶胶质母细胞瘤患者的临床数据。基于训练组构建列线图以验证模型的临床有效性。
共纳入2063例患者。根据随机数字法,1444例患者被分配至训练组,其余619例患者被纳入验证组。基于训练组的1444例数据进行的Cox多因素分析显示,年龄、肿瘤跨中线、转移、手术、化疗和放疗与预后显著相关,P值均小于0.05。在训练组中,该队列总生存(OS)和癌症特异生存(CSS)的一致性指数(C指数)分别为0.712和0.710。OS的校准、受试者工作特征曲线和决策曲线分析显示生存的实际概率与预测概率之间具有良好的一致性。在卡尺值为0.02进行1:1匹配后,共筛选出225例病例进行分析。接受放疗患者的中位生存时间为7个月,未接受放疗患者的中位生存时间为5个月,风险比=1.067,P值小于0.05。
60岁以上、中线占位性病变、未行手术、未行放疗以及未行化疗是额叶胶质母细胞瘤患者的不良预后因素。放射治疗可显著改善额叶胶质母细胞瘤患者的OS和CSS。本研究开发的列线图具有临床应用潜力。